You are here

  • Home
  • Archive
  • Volume 82, Issue 8
  • Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman
  1. Robert BM Landewé1,2,
  2. Juergen Braun3
  1. 1 Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands
  2. 2 Rheumatology, Zuyderland MC, Heerlen, The Netherlands
  3. 3 Ruhr University Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany
  1. Correspondence to Prof Juergen Braun, Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne 44649, Germany; juergen.braun{at}elisabethgruppe.de

http://dx.doi.org/10.1136/annrheumdis-2022-222359

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    With great interest we have read the comments of Gladman et al 1 to our viewpoint.2 We are especially grateful that we were able to provoke a statement of such a large and distinguished group of experts in psoriatic arthritis (PsA). However, it looks like that there is little reason for dissent. Thus, Gladman et al agree with us that post hoc analyses of randomised PsA trials have very little value beyond the generation of testable hypotheses per se, that patient-reported outcomes alone do not suffice to declare axial PsA a distinguishable entity, and that Bath ankylosing spondylitis (AS) disease activity index (BASDAI) and AS disease activity index (ASDAS) are instruments developed to measure disease activity in axial spondyloarthritis (axSpA). Of course, the latter does not necessarily imply that they will not be responsive or discriminatory in PsA — with — or …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors RBML and JB contributed.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles